Actionable news
All posts from Actionable news
Actionable news in NBIX: Neurocrine Biosciences, Inc.,

Neurocrine Bio Soars on Positive Phase 3 Results

Neurocrine Biosciences Inc. (NASDAQ: NBIX) made waves in the market on Thursday morning, despite a weaker performance from the health care sector over the past month. The company announced positive results in its Phase 3 trial of its highly selective small molecule VMAT2 inhibitor. Basically, NBI-98854 showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial.

As a side note, this Phase 3 trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.

Overall, these results from the Kinect 3 study...